androstenediol
Androstenediol, or 5-androstenediol (abbreviated as A5 or Δ5-diol), also known as androst-5-ene-3β,17β-diol, is an endogenous weak androgen and estrogen steroid hormone and intermediate in the biosynthesis of testosterone from dehydroepiandrosterone (DHEA). It is closely related to androstenedione (androst-4-ene-3,17-dione).
Research
746 papers- The potential value of 5-androstenediol in countering acute radiation syndrome.Drug discovery today · 2024
- Dehydroepiandrosterone and Its Metabolite 5-Androstenediol: New Therapeutic Targets and Possibilities for Clinical Application.Pharmaceuticals (Basel, Switzerland) · 2024
- 17α-androstenediol-mediated oncophagy of tumor cells by different mechanisms is determined by the target tumor.Annals of the New York Academy of Sciences · 2012
- Androstenediol analogs as ER-beta-selective SERMs.Bioorganic & medicinal chemistry letters · 2006
- Androstenediol reverses steroid-inhibited wound healing.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2009
via PubMed
Article
8 sectionsContents
- Biological activity
- Chemistry
- Synthesis
- Esters
- Research
- Radiation countermeasure
- Additional images
- References
Androstenediol, or 5-androstenediol (abbreviated as A5 or Δ5-diol), also known as androst-5-ene-3β,17β-diol, is an endogenous weak androgen and estrogen steroid hormone and intermediate in the biosynthesis of testosterone from dehydroepiandrosterone (DHEA). It is closely related to androstenedione (androst-4-ene-3,17-dione).
==Biological activity== Androstenediol is a direct metabolite of the most abundant steroid produced by the human adrenal cortex, DHEA. It is less androgenic than the related compound, Δ4-androstenediol, and has been found to stimulate the immune system. When administered to rats, androstenediol, in vivo, has approximately 1.4% of the androgenicity of DHEA, 0.54% of the androgenicity of androstenedione, and 0.21% of the androgenicity of testosterone.